R Squared’s Janux Therapeutics JANX Stock Holding History

R Squared’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20	Closed	-$1.07K	–	894
2024 Q4	$1.07K	Buy	+20	New	+$1.06K	﹤0.01%	1508

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

R Squared's JANX Position: Q1 2025 in Review

R Squared sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 20 shares — an estimated $1.07K sold.

R Squared first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $1.07K in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

R Squared reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 20 Janux Therapeutics shares in Q1 2025, an estimated $1.07K.
R Squared first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Janux Therapeutics position peaked at $1.07K in Q4 2024.
181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.